Asandeutertinib vs HLX42

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Asandeutertinib

Marketed by TYK Medicines, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05146219 · Phase 2 · completed

The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT06672068 (registry estimate)

Reported efficacy

Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)

Result source: NCT05146219

HLX42

Developed by Shanghai Henlius Biotech

Phase 1 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsandeutertinibHLX42
PFS, median—Trial running · NCT05382728—Not reported
OS, median—Trial running · NCT05382728—Not reported
ORR—Trial running · NCT05382728—Not reported
Duration of response, median—Trial running · NCT05382728—Not reported

PFS, median

Asandeutertinib
—Trial running · NCT05382728
HLX42
—Not reported

OS, median

Asandeutertinib
—Trial running · NCT05382728
HLX42
—Not reported

ORR

Asandeutertinib
—Trial running · NCT05382728
HLX42
—Not reported

Duration of response, median

Asandeutertinib
—Trial running · NCT05382728
HLX42
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HLX42: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Asandeutertinib
Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months NCT05146219 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · HLX42's landscape